Journey Medical (NASDAQ:DERM) Releases Earnings Results, Misses Estimates By $0.03 EPS

Journey Medical (NASDAQ:DERM) issued its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03), Yahoo Finance reports. The company had revenue of $14.86 million during the quarter, compared to analyst estimates of $13.81 million. Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. During the same quarter in the previous year, the firm earned ($0.46) earnings per share.

Journey Medical Stock Up 14.2 %

DERM opened at $4.82 on Wednesday. The firm has a fifty day simple moving average of $5.31. The stock has a market capitalization of $96.46 million, a price-to-earnings ratio of -15.55 and a beta of 0.93. Journey Medical has a 12-month low of $1.78 and a 12-month high of $8.11. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.21 and a quick ratio of 0.94.

Analyst Ratings Changes

DERM has been the topic of several recent analyst reports. Roth Mkm began coverage on shares of Journey Medical in a research note on Friday, June 28th. They set a “buy” rating and a $11.00 target price on the stock. Roth Capital upgraded Journey Medical to a “strong-buy” rating in a report on Friday, June 28th.

Insider Activity

In other news, CFO Joseph Benesch sold 9,324 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $5.47, for a total value of $51,002.28. Following the transaction, the chief financial officer now directly owns 47,331 shares of the company’s stock, valued at $258,900.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 19.42% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.